280 related articles for article (PubMed ID: 30355720)
1. Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy.
Zola M; Daruich A; Matet A; Mantel I; Behar-Cohen F
Br J Ophthalmol; 2019 Aug; 103(8):1184-1189. PubMed ID: 30355720
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.
Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C
Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785
[TBL] [Abstract][Full Text] [Related]
3. MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES.
Gergely R; Kovács I; Schneider M; Resch M; Papp A; Récsán Z; Nagy ZZ; Ecsedy M
Retina; 2017 Jun; 37(6):1084-1091. PubMed ID: 27627749
[TBL] [Abstract][Full Text] [Related]
4. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study.
Schwartz R; Habot-Wilner Z; Martinez MR; Nutman A; Goldenberg D; Cohen S; Shulman S; Guzner-Gur H; Loewenstein A; Goldstein M
Acta Ophthalmol; 2017 Nov; 95(7):e610-e618. PubMed ID: 28653813
[TBL] [Abstract][Full Text] [Related]
5. Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy.
Bousquet E; Dhundass M; Lejoyeux R; Shinojima A; Krivosic V; Mrejen S; Gaudric A; Tadayoni R
Am J Ophthalmol; 2019 Feb; 198():80-87. PubMed ID: 30308202
[TBL] [Abstract][Full Text] [Related]
6. Multimodal retinal imaging in central serous chorioretinopathy treated with oral eplerenone or photodynamic therapy.
Rabiolo A; Zucchiatti I; Marchese A; Baldin G; Sacconi R; Montorio D; Cicinelli MV; Querques L; Bandello F; Querques G;
Eye (Lond); 2018 Jan; 32(1):55-66. PubMed ID: 29265111
[TBL] [Abstract][Full Text] [Related]
7. COMPARISON OF SHORT-TERM EFFICACY BETWEEN ORAL SPIRONOLACTONE TREATMENT AND PHOTODYNAMIC THERAPY FOR THE TREATMENT OF NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY.
Lee JH; Lee SC; Kim H; Lee CS
Retina; 2019 Jan; 39(1):127-133. PubMed ID: 29095358
[TBL] [Abstract][Full Text] [Related]
8. Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR).
Herold TR; Rist K; Priglinger SG; Ulbig MW; Wolf A
Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):221-229. PubMed ID: 27475933
[TBL] [Abstract][Full Text] [Related]
9. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.
Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F
Retina; 2013; 33(10):2096-102. PubMed ID: 23719402
[TBL] [Abstract][Full Text] [Related]
10. COMPARISON OF VISUAL/ANATOMICAL OUTCOMES AND RECURRENCE RATE BETWEEN ORAL SPIRONOLACTONE AND PHOTODYNAMIC THERAPY FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY.
Kim DY; Lee JY; Lee EK; Kim JY
Retina; 2020 Jun; 40(6):1191-1199. PubMed ID: 30897068
[TBL] [Abstract][Full Text] [Related]
11. Spironolactone versus observation in the treatment of acute central serous chorioretinopathy.
Sun X; Shuai Y; Fang W; Li J; Ge W; Yuan S; Liu Q
Br J Ophthalmol; 2018 Aug; 102(8):1060-1065. PubMed ID: 29089356
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy.
Pichi F; Carrai P; Ciardella A; Behar-Cohen F; Nucci P;
Int Ophthalmol; 2017 Oct; 37(5):1115-1125. PubMed ID: 27757733
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
Son BK; Kim K; Kim ES; Yu SY
Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Eplerenone in Chronic Central Serous Chorioretinopathy Refractory to Photodynamic Therapy.
Karagiannis D; Parikakis E; Kontomichos L; Batsos G; Chatziralli I
Semin Ophthalmol; 2019; 34(6):436-441. PubMed ID: 31309849
[No Abstract] [Full Text] [Related]
15. Investigating the efficacy and safety of oral spironolactone in patients with central serous chorioretinopathy.
Yavuz S; Balsak S; Karahan M; Dursun B
J Fr Ophtalmol; 2021 Jan; 44(1):13-23. PubMed ID: 33279285
[TBL] [Abstract][Full Text] [Related]
16. Oral Mineralocorticoid-Receptor Antagonists: Choroidal Parameters Changes Using OCT in Central Serous Chorioretinopathy.
Faghihi H; Mohammadzadeh V; Nabavi A; Faghihi S; Kadivar S; Ghassemi F
Ophthalmic Surg Lasers Imaging Retina; 2019 Nov; 50(11):726-733. PubMed ID: 31755972
[TBL] [Abstract][Full Text] [Related]
17. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
van Dijk EHC; Dijkman G; Boon CJF
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835
[TBL] [Abstract][Full Text] [Related]
18. [Eplerenone treatment in chronic central serous chorioretinopathy].
Sampo M; Soler V; Gascon P; Ho Wang Yin G; Hoffart L; Denis D; Matonti F
J Fr Ophtalmol; 2016 Jun; 39(6):535-42. PubMed ID: 27230892
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by swept source optical coherence tomography angiography (SS OCTA).
Sulzbacher F; Schütze C; Burgmüller M; Vécsei-Marlovits PV; Weingessel B
Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1581-1590. PubMed ID: 31037488
[TBL] [Abstract][Full Text] [Related]
20. TWELVE-MONTH EFFICACY OF INTRAVITREAL BEVACIZUMAB INJECTION FOR CHRONIC, ATYPICAL, OR RECURRENT CENTRAL SEROUS CHORIORETINOPATHY.
Chung YR; Kim JW; Song JH; Park A; Kim MH
Retina; 2019 Jan; 39(1):134-142. PubMed ID: 29077604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
